Neoadjuvant chemotherapy: Early response as a guide for further treatment: Clinical, radiological, and biological

Journal of the National Cancer Institute - Monographs

Volumn , Issue 43, 2011, Pages 138-141

  Untch, Michael ^a   von Minckwitz, Gunter ^b  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b German Breast Group   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; HORMONE RECEPTOR; LAPATINIB; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AGE; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER PATIENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG MEGADOSE; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ULTRASOUND; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; METABOLISM; METHODOLOGY; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; RADIOGRAPHY; REMISSION; TIME; TREATMENT OUTCOME; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOADJUVANT THERAPY; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84855182275     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgr028     Document Type: Article

References (22)

1. Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2005;91(1):1-10.
2. Nakamura S, Ishiyama M, Tsunoda-Shimizu H, et al. Magnetic resonance mammography has limited ability to estimate pathological complete remission after primary chemotherapy or radiofrequency ablation therapy. Breast Cancer. 2007;14(2):123-130.
3. Kumar A, Kumar R, Seenu V, et al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer [published online ahead of print February 13, 2009]. Eur Radiol. 2009;19(6):1347-1357.
4. Schwarz-Dose J, Untch M, Tiling R, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F] fluorodeoxyglucose. J Clin Oncol. 2009;27(4):535-541.
5. von Minckwitz G, Kaufmann M, Kümmel S, et al. Integrated metaanalysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane ± trastuzumab containing chemotherapy. Cancer Res. 2009;69(suppl 2):Abstract 79.
6. von Minckwitz G, Costa S, Raab G, et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol. 2001;19(15):3506-3515.
7. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23(12):2676-2685.
8. von Minckwitz G, Kümmel S, Vogel P, et al. German Breast Group. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst. 2008;100(8):552-562.
9. von Minckwitz G, Kümmel S, Vogel P, et al. German Breast Group. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100(8):542-551.
10. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28(12):2024-2031.
11. Untch M, Moebus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 2009;27(18):2938-2945.
12. Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG Study Groups. J Clin Oncol. 2011;29(25):3351-3357.
13. Untch M, Fasching PA, Konecncy GE, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-identsified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel {+/-} darbepoetin alfa in primary breast cancer - results at the time of surgery. Ann Oncol 2011;22(9):1988-1998.
14. von Minckwitz G, Untch M, Nüesch E, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials [published online ahead of print November 3, 2010]. Breast Cancer Res Treat. 2011;125(1):145-156.
15. Steger GG, Greil R, Jakesz R, et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Res 2009; 69(24 Suppl): abstract nr 1081.
16. Huober J, von Minckwitz G, Denkert C, et al. Effect of neoadjuvant anthracycline-taxane based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study [published online ahead of print]. Breast Cancer Res Treat. 2010;124(1):133-140.
17. Scharl A, Arbeitsgemeinschaft Gynäkologische Onkologie/Mammakarzinom/Ed. Aktuelle Empfehlungen zur Prävention, Diagnostik und Therapie primärer und fortgeschrittener Mammakarzinome. State of the Art 2011. Munich: Zuckschwerdt Verlag, 2011.
18. von Minckwitz G, Eidtmann H, Loibl S, et al.; for the German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie-Brust investigators. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol. 2011;22(2):301-306.
19. Baselga J, Bradbury I, Eidtmann H, et al. on Behalf of the NeoALTTO Study Team. First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer. SABCS. 2010;Abstract 291.
20. Guarneri V, Frassoldati A, Bottini A, et al. Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). J Clin Oncol. 2011;29(suppl; abstr 507).
21. Gerber B, Eidtmann H, Rezai M, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 686 triple-negative primary breast cancers: Secondary endpoint analysis of the GeparQuinto study (GBG 44). J Clin Oncol. 2011;29(suppl; abstr 1006).
22. Bear HD, Tang G, Rastogi P, et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. J Clin Oncol 2011;29(suppl; abstr LBA1005).